See more : Sankyo Tateyama, Inc. (5932.T) Income Statement Analysis – Financial Results
Complete financial analysis of Altimmune, Inc. (ALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altimmune, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Invictus Energy Limited (IVZ.AX) Income Statement Analysis – Financial Results
- Al-Saif Stores for Development & Investment Company (4192.SR) Income Statement Analysis – Financial Results
- China Leadshine Technology Co., Ltd. (002979.SZ) Income Statement Analysis – Financial Results
- Church & Crawford, Inc. (CCWF) Income Statement Analysis – Financial Results
- PCBL Limited (PCBL.BO) Income Statement Analysis – Financial Results
Altimmune, Inc. (ALT)
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 426.00K | -68.00K | 4.41M | 8.19M | 5.80M | 10.33M | 41.50K | 5.23M | 10.64M | 10.19M | 17.91M | 25.18M | 24.27M | 20.99M | 27.55M | 32.91M | 14.64M | 1.85M | 586.07K |
| Cost of Revenue | 477.00K | 68.00K | 551.30K | 33.51M | 17.07M | 18.46M | 18.41M | 7.22M | 5.06M | 4.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.00K |
| Gross Profit | -51.00K | -136.00K | 3.86M | -25.32M | -11.26M | -8.13M | -18.36M | -1.99M | 5.58M | 5.93M | 17.91M | 25.18M | 24.27M | 20.99M | 27.55M | 32.91M | 14.64M | 1.85M | 471.07K |
| Gross Profit Ratio | -11.97% | 200.00% | 87.50% | -309.40% | -194.16% | -78.68% | -44,249.39% | -38.07% | 52.41% | 58.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 80.38% |
| Research & Development | 65.80M | 70.54M | 74.54M | 49.77M | 17.77M | 18.46M | 18.41M | 4.84M | 5.13M | 9.32M | 15.29M | 19.51M | 21.22M | 20.88M | 30.22M | 31.81M | 16.56M | 0.00 | 0.00 |
| General & Administrative | 18.14M | 17.13M | 15.41M | 13.21M | 8.50M | 9.77M | 8.46M | 11.52M | 6.22M | 10.91M | 13.28M | 11.63M | 14.31M | 18.02M | 22.43M | 19.40M | 13.88M | 491.09K | 145.78K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.14M | 17.13M | 15.41M | 13.21M | 8.50M | 9.77M | 8.46M | 11.52M | 6.22M | 10.91M | 13.28M | 11.63M | 14.31M | 18.02M | 22.43M | 19.40M | 13.88M | 491.09K | 145.78K |
| Other Expenses | 12.42M | -32.00K | -373.87K | 24.15K | 15.14K | 277.89K | 5.67K | 7.85K | 8.14K | -762.00 | -6.07K | 47.86K | 461.07K | 5.66M | 872.30K | 813.89K | 705.37K | 153.29K | 0.00 |
| Operating Expenses | 96.36M | 87.67M | 89.95M | 62.98M | 26.27M | 28.22M | 16.17M | 16.49M | 11.50M | 20.38M | 28.75M | 31.44M | 35.99M | 44.55M | 53.52M | 52.02M | 31.15M | 644.38K | 145.78K |
| Cost & Expenses | 96.36M | 87.67M | 89.95M | 62.98M | 26.27M | 28.22M | 16.17M | 16.49M | 11.50M | 20.38M | 28.75M | 31.44M | 35.99M | 44.55M | 53.52M | 52.02M | 31.15M | 644.38K | 260.78K |
| Interest Income | 7.35M | 2.87M | 202.74K | 322.51K | 843.41K | 226.60K | 47.58K | 1.05K | 0.00 | 695.00M | 2.58K | 17.81K | 16.66K | 6.96K | 269.13K | 1.23M | 1.12M | 1.85M | 586.07K |
| Interest Expense | 35.00K | 8.00K | 5.66K | 9.42K | 2.24K | 297.09K | 162.14K | 168.15B | 54.58K | 210.40K | 369.28K | 342.56K | 54.57K | 5.94M | 2.84M | 2.57M | 2.12M | 0.00 | 0.00 |
| Depreciation & Amortization | 477.00K | 500.00K | 551.30K | 298.06K | 387.32K | 302.37K | 139.02K | 135.35K | 141.60K | 149.96K | 182.49K | 303.92K | 461.07K | 1.02M | 872.30K | 813.89K | 655.21K | 0.00 | 0.00 |
| EBITDA | -87.94M | -84.40M | -96.53M | -54.15M | -20.19M | -44.72M | -51.76M | -10.91M | -3.18M | -9.53M | -11.10M | -4.08M | -3.28M | -23.26M | -28.57M | -33.03M | -15.80M | -14.05M | 325.30K |
| EBITDA Ratio | -20,642.02% | 124,855.88% | -1,943.50% | -661.62% | -331.28% | -165.39% | -38,725.67% | -4,344.78% | 16.47% | -98.55% | -59.48% | -23.42% | -79.25% | -59.69% | -77.55% | -7.12% | -134.63% | 65.13% | 55.50% |
| Operating Income | -95.93M | -87.74M | -96.91M | -54.80M | -21.46M | -42.83M | -52.05M | -11.26M | -3.40M | -10.19M | -10.84M | -6.27M | -11.73M | -23.55M | -25.97M | -35.24M | -16.50M | 1.20M | 325.30K |
| Operating Income Ratio | -22,518.54% | 129,029.41% | -2,197.42% | -669.50% | -370.00% | -414.61% | -125,401.20% | -215.37% | -31.98% | -100.01% | -60.51% | -24.89% | -48.32% | -112.19% | -94.28% | -107.09% | -112.70% | 65.13% | 55.50% |
| Total Other Income/Expenses | 7.48M | 2.83M | -176.82K | 337.24K | 886.30K | -2.49M | -18.51K | 4.85K | 3.21M | 297.66K | -4.62M | -758.20K | 7.93M | -11.30M | -6.31M | -1.17M | 2.92M | 15.74M | 0.00 |
| Income Before Tax | -88.45M | -84.91M | -97.09M | -54.46M | -20.58M | -45.32M | -52.06M | 205.02M | -3.38M | -9.89M | -11.66M | -4.72M | -3,797.57B | -34,849.28B | -32.28B | -36.42B | -13.59M | 1.20M | 325.30K |
| Income Before Tax Ratio | -20,762.21% | 124,867.65% | -2,201.43% | -665.38% | -354.72% | -438.68% | -125,445.79% | 3,920.00% | -31.76% | -97.09% | -65.07% | -18.77% | -15,649,592.52% | -165,999,488.89% | -117,168.01% | -110,646.14% | -92.79% | 65.13% | 55.50% |
| Income Tax Expense | 0.00 | -197.00K | -919.51K | -5.42M | -58.50K | -6.15M | -5.64M | 11.17M | 61.75K | 61.75K | 61.75K | 195.53K | -7.93M | 15.93M | 6.31M | 17.30M | -2.87M | 187.00K | 48.00K |
| Net Income | -88.45M | -84.71M | -96.17M | -49.04M | -20.52M | -39.17M | -46.43M | 193.85M | -3.44M | -9.96M | -11.72M | -4.92M | -3.80M | -34.85M | -32.28M | -36.42M | -13.59M | 1.02M | 277.30K |
| Net Income Ratio | -20,762.21% | 124,577.94% | -2,180.58% | -599.20% | -353.71% | -379.16% | -111,860.32% | 3,706.44% | -32.34% | -97.70% | -65.42% | -19.54% | -15.65% | -166.00% | -117.17% | -110.65% | -92.79% | 55.01% | 47.31% |
| EPS | -1.66 | -1.81 | -2.33 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 | -30.55 | -24.07 | -323.59 | -351.19 | -476.15 | -431.69 | -11.48K | 12.00 |
| EPS Diluted | -1.66 | -1.81 | -2.33 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 | -30.55 | -24.07 | -323.59 | -351.19 | -476.15 | -431.69 | -11.48K | 9.00 |
| Weighted Avg Shares Out | 53.25M | 46.93M | 41.28M | 25.64M | 13.12M | 2.80M | 426.83K | 230.38K | 213.28K | 191.78K | 168.86K | 161.08K | 157.77K | 107.70K | 91.92K | 76.48K | 31.48K | 1.89K | 26.23K |
| Weighted Avg Shares Out (Dil) | 53.25M | 46.93M | 41.28M | 25.64M | 13.12M | 2.80M | 426.83K | 230.38K | 213.28K | 191.78K | 168.86K | 161.08K | 157.77K | 107.70K | 91.92K | 76.48K | 31.48K | 1.89K | 27.74K |
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at...
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide shows strong potential in obesity and MASH, preserving lean mass while reducing VAT, which could make it a market leader among GLP-1s. Recent Phase II data reveals pemvidutide's lean loss ratio of 21.9%, comparable to diet and exercise, and...
Five Top Obesity Stocks to Buy and Hold Long Term
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose tissue (VAT) at Week 48 has been corrected from 25.6%...
ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024
LAS VEGAS, NV / ACCESSWIRE / September 10, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for August 2024. According...
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor...
ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024
LAS VEGAS, NV / ACCESSWIRE / September 9, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced their participation in the upcoming iFX Bangkok...
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented...
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Weight loss drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune's pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation...
Source: https://incomestatements.info
Category: Stock Reports